stockrow
Saturday 7 November 2026
Export ALMS’s income statement to Excel — free account
Alumis Inc.
ALMS Healthcare Biotechnology
Alumis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.1 million.
- Revenue
- −37.7%
- EPS
- −242.3%
- Free cash flow
- +23.6%
Quarter to June 2026, against a year earlier
6.02
0.17
+2.91%
Follow ALMS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
485.70 | 327.88 | 34.51 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(44.09) | (31.64) | (11.54) | (3.75) | |
P/B ratio |
7.95 | 4.86 | 2.75 | 1.08 | |
Price to Tangible BV |
8.11 | 5.34 | 3.32 | 1.24 | |
EV/Sales |
417.80 | 265.63 | 21.68 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.80) | (5.93) | (1.41) | (0.10) | |
EV/FCF |
(8.79) | (5.92) | (1.41) | (0.10) | |
Quick Ratio |
6.59 | 7.38 | 4.21 | 5.77 | |
Current Ratio |
6.74 | 7.51 | 4.34 | 6.01 | |
Net Debt/EBITDA |
4.73 | 5.36 | 3.23 | 3.30 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.02 | 0.06 | 0.00 | |
Operating CF/Net income |
0.57 | 0.94 | 0.77 | 1.00 | |
Capex/Depreciation |
(0.01) | (0.19) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
5,134.60% | 4,683.52% | 4,291.60% | 4,735.53% | |
Selling, General and Administrative Expense of Revenue |
1,405.29% | 1,068.93% | 808.14% | 944.92% | |
Intangible Assets out of Total Assets |
0.02 | 0.08 | 0.12 | 0.10 | |
Share Based Compensation of Revenue |
858.78% | 708.73% | 420.27% | 473.72% | |
Graham Net Nets |
0.11 | 0.16 | 0.25 | 0.70 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.48%) | (8.64%) | (30.56%) | (95.97%) | |
Free Cash Flow Yield |
(9.79%) | (13.69%) | (44.61%) | (89.89%) | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.02 | |
Operating CF per Share |
(0.64) | (0.70) | (0.85) | (1.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.64) | (0.70) | (0.85) | (1.07) | |
Cash per Share |
3.93 | 4.18 | 3.63 | 3.63 | |
Shareholders Equity per Share |
3.54 | 4.53 | 3.54 | 3.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.54 | 4.53 | 3.54 | 3.70 | |
Free Cash Flow |
(81.74) | (87.25) | (71.91) | (110.91) | |
Working Capital |
437.85 | 461.50 | 244.91 | 327.87 | |
Capital Expenditures |
(0.24) | (0.16) | 0.00 | 0.00 | |
Net Current Asset Value |
405.62 | 427.84 | 207.59 | 290.05 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.14 | 0.09 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
13.89 | 9.53 | 9.87 | 5.50 | |
Average Assets |
585.77 | 466.44 | 376.47 | 450.29 | |
Average Common Equity |
468.74 | 367.67 | 280.70 | 366.58 |
Columns are period end dates · fundamentals updated 26 Oct 2026